[{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear\u00ae in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Novitium Pharma LLC","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$372.5 million","upfrontCash":"$89.5 million","newsHeadline":"ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Padagis","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advisory - Apotex Recalls Apo-Acyclovir Tablets Due to a Nitrosamine Impurity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck\u2019s PREVYMIS\u2122 for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Acyclovir Cream","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Alti-Acyclovir
CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 200MG/5ML, TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Acyclovir is a synthetic purine nucleoside analogue having high affinity for the enzyme thymidine kinase encoded by HSV and VZV. It has shown in vitro and in vivo inhibitory activity against herpes simplex virus types 1, 2 and varicella-zoster virus (VZV).
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex.
Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
Under the new Agreement, Sol-Gel has retained collaboration rights to two generic programs acyclovir cream and ivermectin cream related to four generic drug candidates that it believes to have the most value-generating potential.
Novitium Pharma's lead drug, Acyclovir oral suspension, is a synthetic nucleoside analogue active against herpesviruses. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV.